Daniel S. Lorrain - 30 Jan 2026 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
Chief Scientific Officer
Signature
/s/ Peter Slover, Attorney-in-Fact
Issuer symbol
CTNM
Transactions as of
30 Jan 2026
Net transactions value
$0
Form type
4
Filing time
30 Jan 2026, 16:54:35 UTC
Previous filing
06 Jan 2026
Next filing
05 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lorrain Daniel S. Chief Scientific Officer 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO /s/ Peter Slover, Attorney-in-Fact 30 Jan 2026 0001861550

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTNM Stock Option (right to buy) Award $0 +160,000 $0.000000 160,000 30 Jan 2026 Class A Common Stock 160,000 $14.26 Direct F1
transaction CTNM Stock Option (right to buy) Award $0 +6,500 $0.000000 6,500 30 Jan 2026 Class A Common Stock 6,500 $14.26 By Spouse F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.
F2 Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's spouse's continuous service.